Cited by 22Receptor Mechanisms and SignalingNeuroscience and Neuropharmacology ResearchTreatment of Major Depression

Antidepressants, β-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions

Golan, Moran, Schreiber, Gabriel, Avissar, Sofia·2009·Current Pharmaceutical Design

Abstract

G protein-coupled receptors (GPCR) have generated considerable interest in the pharmaceutical industry as drug targets. Theories concerning antidepressant targets of action suggested pre-synaptic monoamine reuptake mechanisms regulating GPCR activities including delayed receptor desensitization and down-regulation. GRKs and beta-arrestins translocate to the cell membrane and bind to agonist-occupied receptors. This uncouples these receptors from G proteins and promotes their internalization, leading to desensitization and down-regulation. Thus, GRKs and beta-arrestins serve as negative regulators of GPCR signaling. Recently, GPCR have been demonstrated to elicit signals through interaction with beta-arrestin as scaffolding proteins, independent of heterotrimeric G-protein coupling. beta-arrestins function as scaffold proteins that interact with several cytoplasmic proteins and link GPCR to intracellular signaling pathways such as MAPK cascades. Recent work has also revealed that beta-arrestins translocate from the cytoplasm to the nucleus and associate with transcription cofactors such as p300 and CREB. They also interact with regulators of transcription factors. We review findings concerning effects of antidepressants on GRKs and beta-arrestins and the plethora of antidepressants effects on signal transduction elements in which GRKs and beta-arrestins serve as signaling scaffold proteins, and on transcription factors and cofactors in which beta-arrestins mediate regulation of transcription. The emergence of G-protein-independent signaling pathways, through beta-arrestins, changes the way in which GPCR signaling is evaluated, from a cell biological to a pharmaceutical perspective and raises the possibility for the development of pathway specific therapeutics e.g., antidepressant medications targeting GRKs and beta-arrestin regulatory and signaling proteins.

Integrity signals

Registry

Crossref · 10.2174/138161209788168038

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Golan, M., Schreiber, G., & Avissar, S.
Affiliations
Ben-Gurion University of the Negev (IL)
Venue
Current Pharmaceutical Design
Published
2009-05-01
Volume
15
Issue
14
Pages
1699-1708
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2094317231
Cited by
22
References
126
Citations by year
2026: 1 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2013: 3 · 2012: 3
FWCI
1.34
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
antidepressants, beta-arrestin, G protein-coupled receptors, G protein-coupled receptor kinases, receptor desensitization, receptor down-regulation, scaffold proteins, G protein-independent signaling, MAPK signaling, transcriptional regulation, CREB, P300, monoamine reuptake
MeSH terms
beta-Arrestins, Animals, Antidepressive Agents, Depressive Disorder, Humans, Transcription, Genetic, Signal Transduction, Drug Delivery Systems, Arrestins, Receptors, G-Protein-Coupled, G-Protein-Coupled Receptor Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review